Lifestance Health Group (LFST) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue rose 20% year-over-year to $312.3 million, driven by higher visit volumes and clinician growth, with visit volumes up 15% to 2.0 million and the clinician base growing 14% to 6,984.

• Adjusted EBITDA more than doubled to $28.6 million (9.2% margin), and Center Margin increased 34% to $97.8 million (31.3% of revenue).

• Net loss narrowed to $23.3 million from $45.5 million in Q2 2023, reflecting improved operating leverage.

• Cash and cash equivalents at quarter-end were $87.0 million, with net long-term debt of $279.5 million.

• Continued investment in digital tools, operational model, and virtual care to enhance patient and clinician experience.

Financial highlights

• Q2 2024 revenue was $312.3 million, up from $259.6 million in Q2 2023 (+20% year-over-year).

• Center Margin rose 34% year-over-year to $97.8 million (31.3% of revenue).

• Adjusted EBITDA increased 103% year-over-year to $28.6 million (9.2% of revenue).

• Free Cash Flow for Q2 2024 was $38.9 million, with $87 million in cash at quarter end.

• Net loss per share improved to $(0.06) from $(0.13) year-over-year.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $1.2–$1.242 billion.

• Center Margin guidance increased to $363–$383 million; Adjusted EBITDA to $90–$100 million; positive Free Cash Flow expected.

• Q3 2024 guidance: revenue $290–$310 million, Center Margin $83–$95 million, Adjusted EBITDA $15–$21 million.

• Fewer than 10 de novo centers expected to open in 2024, with no M&A spend planned.

• Stock-based compensation expected at the lower end of $80–$95 million range.